Been looking at Iovance Biotherapeutics (IOVA) lately and there's actually something interesting happening here if you're willing to take on serious risk.

Their main product Amtagvi just got FDA approval for melanoma early last year, and the commercial traction has been solid. FY2025 revenue hit $263.5 million, which is a 60.6% jump year-over-year. Not bad for a biotech company still in early commercialization phase. They're also pushing into Europe, UK, and Australia for melanoma, plus they got approval in Canada already.

What caught my attention though is the expansion potential. They're testing Amtagvi across multiple cancer types and just got Fast Track Designation from the FDA for non-small cell lung cancer treatment. If they can capture even a decent slice of a massive market like NSCLC over the next decade through 2036, this stock could legitimately move.

But here's the catch—and it's a big one. Amtagvi is basically a personalized cell therapy, which means it's complex as hell. They have to extract patient cells, manufacture the drug for each individual person, then administer it via IV after chemo. The whole process takes about 34 days and can only happen at specialized centers with trained staff. This isn't a simple pill you pop. The manufacturing costs and logistical complexity are brutal, which makes profitability a real question mark.

Plus you've got all the usual biotech landmines: clinical setbacks, regulatory hurdles, execution risk. This is the kind of stock that either moons or tanks depending on how well they navigate the next few years.

So yeah, if you're comfortable with high volatility and the real possibility of losing money, there's potential here. But this definitely isn't for risk-averse investors. Do your own research before touching this one.